Stay updated on GA 40 mg Injection vs Placebo in RRMS - Clinical Trial

Sign up to get notified when there's something new on the GA 40 mg Injection vs Placebo in RRMS - Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the GA 40 mg Injection vs Placebo in RRMS - Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T22:42:51.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    4 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a potential update in the number of confirmed relapses during the 12-month placebo controlled period in a study related to the efficacy of Glatiramer Acetate (GA) injection for subjects with Relapsing-Remitting Multiple Sclerosis (RRMS).
    Difference
    0.1%
    Check dated 2024-06-06T14:15:19.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The webpage has been updated to include detailed eligibility criteria for study participants, specifying that subjects must have a confirmed MS diagnosis and meet certain health conditions. Previously, no information was provided under Participation Criteria Collaborators and Investigators.
    Difference
    17%
    Check dated 2024-05-22T19:15:11.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.6%
    Check dated 2024-04-30T22:46:58.000Z thumbnail image

Stay in the know with updates to GA 40 mg Injection vs Placebo in RRMS - Clinical Trial

Enter your email address, and we'll notify you when there's something new on the GA 40 mg Injection vs Placebo in RRMS - Clinical Trial page.